ORIC partners with Cancer Research UK to move CIP2A‑targeted drug into clinical trials
ORIC Pharmaceuticals entered an agreement with Cancer Research UK to fund and run early clinical studies of ORIC‑259, a small‑molecule degrader that targets the CIP2A protein. The UK centre will design, sponsor and execute CTA‑enabling work and Phase 1/2 trials, while ORIC keeps an option to buy back the rights after those data are available. The partnership also provides for milestone payments and royalties to Cancer Research UK.
Why it matters
The deal gives ORIC a fully funded path to test its first‑in‑class CIP2A‑targeted therapy, preserving cash for its late‑stage pipeline. If Phase 1/2 results are positive, ORIC could regain full control of the asset and potentially add a novel oncology candidate to its portfolio.
Key facts
- 1Cancer Research UK will fully fund, sponsor, design, and execute CTA‑enabling studies and Phase 1/2 clinical development of ORIC‑259. globenewswire.com
- 2ORIC retains an exclusive option to reacquire rights to ORIC‑259 after Phase 1/2 data are obtained. globenewswire.com
- 3Cancer Research UK is eligible for downstream milestone payments and royalties. globenewswire.com
- 4ORIC‑259 is a small‑molecule mRNA degrader that targets the CIP2A protein, which is linked to cancer progression. globenewswire.com
- 5Preclinical studies indicated the compound reduced tumor growth in models both sensitive and resistant to PARP inhibitors, particularly in cancers with homologous recombination deficiency. globenewswire.com
Summary written by AlphAI from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.